Source comparison
MK-677 Dosage Nitrogen Retention Comparison
10mg 35–45% 8–12% None Minimal Subtherapeutic. Insufficient IGF-1 response for meaningful anabolic effect in most subjects 15mg 50–65% 15–20% Mild (1–2kg) Minimum effective dose. Suitable for recomposition or deficit preservation, low side effect burden 25mg 8
This comparison does not assign a generated winner or score.
- 10mg
- 35–45%
- 8–12%
- None
- Minimal
- Subtherapeutic. Insufficient IGF-1 response for meaningful anabolic effect in most subjects
- 15mg
- 50–65%
- 15–20%
- Mild (1–2kg)
- Minimum effective dose. Suitable for recomposition or deficit preservation, low side effect burden
- 25mg
- 80–95%
- 22–28%
- +3–6mg/dL
- Moderate (2–3kg)
- Optimal dose. Maximal nitrogen retention with acceptable metabolic cost, aligns with clinical trial standard
- 30mg
- 95–110%
- 20–25%
- +6–10mg/dL
- Significant (3–5kg)
- Diminishing returns. IGF-1 plateau with rising insulin resistance, water retention confounds lean mass measurement
- 50mg
- 100–120%
- 18–23%
- +10–15mg/dL
- Severe (4–7kg)
- Counterproductive. Metabolic interference reduces net protein synthesis despite elevated IGF-1, high side effect rate